28O TalaCom: Phase Ib investigator-initiated trial combining talazoparib and axitinib in patients with DNA damage response mutated cancers or BRCA1/2 wildtype ovarian cancer incorporating prospective intrapatient dose titration
Year: 2025
Type: article
Abstract: Angiogenic inhibition suppresses BRCA expression, inducing a ‘BRCAness’ tumor phenotype and sensitivity to PARP inhibitors (PARPi). We evaluated the PARPi talazoparib (tala) + VEGFR inhibitor axitib (axi) in patients (pts) with advanced cancers with or without DNA damage response (DDR) mutations (NCT04693468).
Source: ESMO Open
Authors: N.Y.L. Ngoi, J. Rodon, E.E. Dumbrava, B. Garmezy, D.S. Hong, S. Piha-Paul, A.M. Tsimberidou, S. Fu, A. Naing, P.R. Pohlmann, T-Y. Tang, H. Clemente, J. Rhudy, C. Valladolid, C. Salguero, N.A. Velez, H.T. Tran, F. Meric-Bernstam, T.A.A. Yap
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W4408217361